Research progress of PD-1/PD-L1 pathway inhibitor in the immunotherapy of digestive system neoplasm

doi:10.12092/j.issn.1009-2501.2018.08.018

Abstract

Abstract:

Programmed cell death-1(PD-1) is an important co-inhibitory molecule expressing on T cell that has negative regulations on immune responses. When PD-1 bound to its ligand programmed cell death-ligand (PD-L1), PD-1/PD-L1 pathway can restrain the immune microenvironment, leading to the down-regulation of tumor-specific T cell activity, and contribute to tumor cells avoiding the immune surveillance and immune escape. PD-1/PD-L1 inhibitors may block its signaling pathway and enhance immune responses, thus inhibiting the growth of tumor cells. In this review, we discuss the therapeutics use of PD-1/PD-L1 monoclonal blocking antibodies in the immunotherapy of digestive system neoplasm.

Key words: PD-1/PD-L1, pathway inhibitors, neoplasms of digestive system, immunity therapy

CLC Number:

R735

MENG Qiuhua, TIAN Jing, QIN Feizhang, QIN Yang, DONG Min. Research progress of PD-1/PD-L1 pathway inhibitor in the immunotherapy of digestive system neoplasm[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(8): 942-948.

References

［1］Chen W, Zheng R, Baade PD, et al. Cancer Statistics in China, 2015［J］. CA Cancer J Clin, 2016, 66(2): 115-132.
［2］Saito T, Yokosuka T, Hashimoto-Tane A. Dynamic regulation of T cell activation and co-stimulation through TCR-microclusters［J］. FEBS Lett, 2010, 584(24):4865-4871.
［3］Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion ［J］. Science, 2011, 331(6024):1565-1570.
［4］Li K, Tian H. Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy ［J］. J Drug Target, 2018, 20:1-13.
［5］Liu B, Song Y, Liu D. Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy［J］. J Hematol Oncol, 2017, 10(1):174.
［6］Ishida Y, Agata Y, Shibahara K, et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death ［J］. EMBO J, 1992, 11(11): 3887-3895.
［7］Sidorenko SP , Clark EA. The dual-function CD150 receptor subfamily: the viral attraction［J］. Nat Immunol, 2003, 4(1):19-24.
［8］Pedoeem A, Azoulay-Alfaguter I, Strazza M, et al. Programmed death-1 pathway in cancer and autoimmunity［J］.Clin Immunol , 2014, 153(1):145-152.
［9］Fife BT, Pauken KE, Eagar TN, et al. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal［J］. Nat Immunol, 2009, 10(11):1185-1192.
［10］Dai S, Jia R, Zhang X, et al. The PD-1/PD-Ls pathway and autoimmune diseases［J］. Cell Immunol, 2014, 290(1):72-79.
［11］Gettinger SN, Horn L, Gandhi L, et al. Overall survival and long-term safety of Nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer［J］. J Clin Oncol, 2015, 33(18):2004-2012.
［12］Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial［J］. Lancer, 2017, 390(10111):2461-2471.
［13］El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial［J］. Lancet, 2017, 389(10088):2492-2502.
［14］Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study［J］. Lancet Oncol, 2017, 18(9):1182-1191.
［15］Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma［J］. N Engl J Med, 2018, 378(14):1277-1290.
［16］Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus Ipilimumab in lung cancer with a high tumor mutational burden ［J］. N Engl J Med, 2018, 378(22):2093-2104.
［17］Grimm MO, Oppel-Heuchel H, Foller S , et al. Treatment with PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors : Immune-mediated side effects［J］. Urologe A, 2018, 57(5):543-551.
［18］Muro K, Chung HC, Shankaran V, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial［J］. Lancet Oncol, 2016, 17(6):717-726.
［19］Falchi L, Sawas A, Deng C, et al. High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory hodgkin lymphoma previously exposed to epigenetic therapy［J］. J Hematol Oncol, 2016, 9(1):132.
［20］Saito H, Kono Y, Murakami Y, et al. Highly activated PD-1/PD-L1 pathway in gastric cancer with PD-L1 expression ［J］. Anticancer Res, 2018, 38(1):107-112.
［21］Jung HI, Jeong D, Ji S, et al. Overexpression of PD-L1 and PD-L2 is associated with poor prognosis in patients with hepatocellular carcinoma［J］. Cancer Res Treat, 2017, 49(1):246-254.
［22］Yagi T, Baba Y, Ishimoto T, et al. PD-L1 expression, tumor-infiltrating lymphocytes, and clinical outcome in patients with surgically resected esophageal cancer ［J］. Ann Surg, 2017, dol:10.1097/SLA.0000000000002616.
［23］Valentini AM, Di Pinto F, Cariola F, et al. PD-L1 expression in colorectal cancer defines three subsets of tumor immune microenvironments［J］. Oncotarget, 2018, 9(9):8584-8596.
［24］Torre LA, Bray F, Sieqel RL, et al. Global cancer statistics,2012［J］.CA Cancer J Clin, 2015, 65(2):87-108.
［25］Long J, Lin J, Wang A, et al. PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy［J］. J Hematol Oncol, 2017, 10(1):146.
［26］Mazzolini GD, Malvicini M. Immunostimulatory monoclonal antibodies for hepatocellular carcinoma therapy. trends and perspectives［J］. Medicina (B Aires), 2018, 78(1):29-32.
［27］Yunching Chen, Ramjiawan RR, Thomas Reiberger, et al. CXCR4 inhibition in tumor microenvironment facilitates anti-PD-1 immunotherapy in sorafenib-treated HCC in mice［J］. Hepatology, 2015, 61(5):1591-1602.
［28］Moris D, Rahnemai-Azar AA, Zhang X, et al. Program death-1 immune checkpoint and tumor microenvironment in malignant liver tumors［J］. Surg Oncol, 2017, 26(4):423-430.
［29］Pennathur A, Gibson MK, Jobe BA, et al. Oesophageal carcinoma［J］. Lancet, 2013, 381(9864):400-412.
［30］Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes［J］. Nature, 2013, 499(7457):214-218.
［31］Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer［J］.Science, 2015, 348(6230):124-128.
［32］Ohigashi Y, Sho M, Yamada Y, et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer［J］. Clin Cancer Res, 2005, 11(8):2947-2953.
［33］Doi T, Piha-Paul SA, Jalal SI, et al. Safety and antitumor activity of the anti-programmed death-1 antibody pembrolizumab in patients with advanced esophageal carcinoma［J］. J Clin Oncol, 2018, 36(1):61-67.
［34］Kudo T, Hamamoto Y, Kato K, et al. Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial［J］. Lancet Oncol, 2017, 18(5):631-639.
［35］Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon［J］. Science, 1993, 260(5109):816-819.
［36］Diaz LA, Le DT. PD-1 blockade in tumors with mismatch-repair deficiency［J］. N Engl J Med, 2015, 373(20):1979.
［37］Lin AY, Lin E. Programmed death 1 blockade, an achilles heel for MMR-deficient tumors［J］. J Hematol Oncol, 2015, 8:124.
［38］Kamisawa T, Wood LD, Itoi T, et al. Pancreatic cancer［J］.Lancet, 2016,388(10039):73-85.
［39］Feng M, Xiong G, Cao Z , et al. PD-1/PD-L1 and immunotherapy for pancreatic cancer［J］. Cancer Lett, 2017, 407:57-65.
［40］Soares KC, Rucki AA, Wu AA, et al. PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors［J］. J Immunother, 2015, 38(1): 1-11.
［41］Zhou NX, Huang ZQ, Zhang WZ, et al. The comprehensive analysis of the clinical classification，surgical methods and long term effects of 402 cases of hilar cholangiocarcinoma［J］. Chin J Surg, 2006, 44(23):1599 -1603.
［42］刘谋泽, 李浩, 张伟. 肝内胆管癌病理机制表观基因组学研究进展［J］.中国临床药理学与治疗学, 2014, 19(11):1294-1298.
［43］Gani F, Nagarajan N, Kim Y, et al. Program death 1 immune checkpoint and tumor microenvironment: implications for patients with intrahepatic cholangiocarcinoma［J］. Ann Surg Oncol, 2016, 23(8):2610-2617.
［44］Ye Y, Zhou L, Xie X, et al. Interaction of B7-H1 on intrahepatic cholangiocarcinoma cells with PD-1 on tumor-infiltrating T cells as a mechanism of immune evasion［J］. J Surg Oncol, 2009, 100(6):500-504.